IL6 and cancer: The ultimate goal for cancer immunological study is to achieve a treatment outcome where cancer-promoting cytokine signaling (TNFα, IL-1, IL-6, IL-17 and IL-23) is blocked to slow down cancer cell growth and reduce their survival and therapy resistance (8, 123).